Ultragenyx Receives Conditional UK Marketing Authorization for Dojolvi
The U.K. drug regulator has granted conditional marketing authorization to Ultragenyx Pharmaceutical (RARE) for its rare disease therapy, triheptanoin, marketed under the name Dojolvi. The medication is indicated for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD refers to a group of rare metabolic diseases where patients experience impaired conversion of fat into energy. This regulatory approval marks a significant step in expanding the geographic availability of Ultragenyx's specialized metabolic treatments.
Tickers: $RARE